Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Anheuser-Busch Inbev SA (BUD) vs Cardinal Health Inc (CAH) Price & Performance

Anheuser-Busch Inbev SATrade
Cardinal Health IncTrade

Price performance (Past 24H)

Key statistics

Anheuser-Busch Inbev SA vs Cardinal Health Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.11 (market cap $159.01B), while Cardinal Health Inc trades at $236.56 (market cap $55.88B). The key difference: Anheuser-Busch Inbev SA is far larger — about 2.8× Cardinal Health Inc's market cap, and Anheuser-Busch Inbev SA pays the higher dividend (1.67%). Which is the better fit depends on your goals.

BUDCAH
Market Cap
$159.01B$55.88B
Sector
Consumer StaplesHealth
52-Week High
$86.48$240.26
52-Week Low
$57.93$146.04
Enterprise Value
$223.42B$59.91B
Dividend Yield
1.67%0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Anheuser-Busch Inbev SA

BUD trades at $83.09, down 0.8% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q1 and Q2 2026 but missing in Q4 2025. The company maintains solid profitability with a 14.9% net income margin and positive cash flow trends. News highlights institutional activity and earnings discussions, with a consensus price target of $90.17 suggesting upside potential.

The outlook for BUD is positive, driven by earnings growth projections and a favorable valuation with a P/E of 17.37. Risks include competitive pressures and macroeconomic volatility, but institutional support and bullish analyst ratings indicate confidence in continued performance. The stock presents a growth opportunity with manageable risks for investors seeking exposure to the consumer staples sector.

Cardinal Health Inc

Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.

Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Anheuser-Busch Inbev SA

Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.

Read more on BUD

About Cardinal Health Inc

Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Read more on CAH